A Phase 3 interventional study of Jaktinib in Alopecia Areata, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.
Among the 24 studies in Alopecia Areata with a site in China, this one is the 9th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 in phase 3, and was the 9th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 12–18
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 18–65
Pfizer · Sites in China, United States, Canada and 2 more countries
Ages 12+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–80 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Canada and 4 more countries
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 11
First in 2012; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 315 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 163 across the 22 interventional studies, 300 across the 2 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 10 most frequent:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd has 4 studies filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
3 of the studies in Alopecia Areata with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT06573593Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEfficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study | 2026-12-31 |
| NCT07533006Eli Lilly and CompanyA Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Alopecia Areata with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will administer the study product twice per day for 24 weeks, for the safety assessment.
Drug: Jaktinib
75mg BID
Number of subjects reporting treatment-emergent adverse events
Patients with treatment-emergent adverse events/all patients \*100%
Time frame: Baseline through week 24
Ran from Mar 2022 to primary completion in Jun 2024, 27 months.
Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Jaktinib
Suzhou Zelgen Biopharmaceuticals Co.,Ltd →